论文部分内容阅读
目的:对71例Ⅲ-N2期非小细胞肺癌综合治疗的病例进行生存分析。方法:我院2007年3月至2014年3月诊断为Ⅲ-N2期的非小细胞肺癌患者71例,所有患者均接受手术、诱导或辅助化疗及术后放疗。采用Kaplan-Meier法对以上患者的总生存期(overall survival,OS)和无病生存期(disease free survival,DFS)进行分析。结果:71例患者的中位生存期为32个月,1年、3年和5年生存率分别为84.5%、49.6%和35.5%;1年、3年和5年无病生存率分别为70.4%、41.8%和27.4%;9例患者(12.6%)出现局部复发;鳞状细胞癌患者的中位生存期为43个月,而腺癌患者的中位生存期为21个月。鳞癌患者1年、3年、5年的OS和DFS分别为85%、60%、42.5%和80.0%、55.0%、34.2%;腺癌患者1年、3年、5年的OS和DFS分别为77.1%、42.0%、36.0%和60.0%、28.6%、28.6%,两组OS和DFS均无显著性差异。结论:不同细胞类型非小细胞肺癌综合治疗生存期存在差异
Objective: To analyze the survival of 71 patients with stage Ⅲ-N2 non-small cell lung cancer. Methods: From March 2007 to March 2014, 71 patients with non-small cell lung cancer diagnosed as stage Ⅲ-N2 were recruited in our hospital. All patients received operation, induction or adjuvant chemotherapy and postoperative radiotherapy. Kaplan-Meier method was used to analyze the overall survival (OS) and disease free survival (DFS). Results: The median survival of 71 patients was 32 months. The 1-year, 3-year and 5-year survival rates were 84.5%, 49.6% and 35.5% respectively. The 1-year, 3-year and 5-year disease- 70.4%, 41.8% and 27.4%, respectively. Nine patients (12.6%) had local recurrence. The median survival of patients with squamous cell carcinoma was 43 months, while the median survival of patients with adenocarcinoma was 21 months. Patients with squamous cell carcinoma had OS and DFS of 85%, 60%, 42.5% and 80.0%, 55.0% and 34.2% at 1 year, 3 years and 5 years respectively. Patients with adenocarcinoma had OS and DFS of 1 year, 3 years and 5 years Respectively, 77.1%, 42.0%, 36.0% and 60.0%, 28.6% and 28.6% respectively. There was no significant difference in OS and DFS between the two groups. Conclusion: The survival of different cell types in NSCLC is different